News Roundup: US Drug Overdose Deaths Reach Record High, Study Examines High-Dose Buprenorphine Therapy in Emergency Departments
Here’s a roundup of the latest news coverage from Drug Topics®.
Don’t waste time digging through articles to find the most up-to-date and important news. Drug Topics® has you covered with our weekly news roundup of the latest pharmacy-related news you should know before the weekend begins.
Here’s a roundup of the latest news coverage from Drug Topics®.
Antidepressant Use Can Improve Diabetes Outcomes in Patients With Depression
Patients with diabetes and depression may have a lower risk of mortality and diabetes complications when taking antidepressants regularly, according to a new study.
Efficacy, Safety of Dapagliflozin in Stage 4 Chronic Kidney Disease
Dapagliflozin was shown to significantly reduce the risk of kidney failure and prolong survival in patients with advanced chronic kidney disease regardless of diabetes status.
Study Examines High-Dose Buprenorphine Therapy in Emergency Departments
High-dose buprenorphine therapy, provided under emergency department care, is safe and well-tolerated in patients with opioid use disorder, according to study results.
US Drug Overdose Deaths Reach Record High in 2020
Drug overdose deaths, including opioid-related deaths, have increased rapidly in the United States in recent years, according to preliminary data from the CDC.
Pharmacy Groups Back Washington State Court Decision on ‘Unsustainable’ CMS Reimbursement Law
WSPA, NPCA, and NACDS fully support the court decision requiring CMS to reconsider the below-cost reimbursement plan.
AZSTARYS is now available for treating ADHD
AZSTARYS (serdexmethylphenidate and dexmethylphenidate) is available for prescription to help provide rapid and extended duration of attention-deficit/hyperactivity disorder (ADHD) symptoms.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
